About

We have developed two products:

Hemopure® [hemoglobin glutamer – 250 (bovine)], for use in humans, and
Oxyglobin® [hemoglobin glutamer – 200 (bovine)] our veterinary product.

Hemopure is not approved in the US, and available only under investigational status through the FDA expanded access program to qualifying patients with severe, life threatening anemia for whom blood transfusion is not an option, and who have exhausted all other treatment options. Blood transfusion may not be an option due to religious beliefs, or because no compatible blood is available for a patient needing transfusion. Additional information on expanded access can be found at:
https://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassionateUse/default.htm

Oxyglobin is the only oxygen carrying solution approved by the FDA and the European Medicines Agency (EMA) to treat all cause canine anemia.

When our products are infused into the bloodstream, the chemically stabilized hemoglobin molecules carry oxygen in the plasma (the fluid part of blood) and can also facilitate the release of oxygen from remaining red blood cells (RBC), thereby increasing diffusion of oxygen to tissues. If necessary, this effect can be extended over time by repeat dosing to provide a continuous oxygen bridge until the patients receive other appropriate therapy.

Hemoglobin, the native protein responsible for transporting oxygen is normally contained within circulating RBCs. However, our products consist of hemoglobin that has been extracted from the RBCs of cattle and then purified, chemically cross-linked for stability and formulated in a balanced salt solution similar to Lactated Ringer's Solution.

On a gram-for-gram basis, stabilized hemoglobin molecules in our products hold the same amount of oxygen as the hemoglobin molecules in RBCs, but with a higher P50 (40 mM Hg), they release the oxygen more readily. In addition, data from preclinical studies suggest that introducing our products into the bloodstream may help RBCs offload more oxygen to the tissues than they would otherwise.

Scientific advisory board

HbO2 Therapeutics collaborates with institutions and key opinion leaders around the world. They include, but are not limited to specialists in transfusion medicine, cardiology, trauma surgery, hematology/oncology, and transplantation.

Management

Led by a team with decades of success

Former CEO of OPK Biotech LLC which developed the first approved HBOC for human use. Mr. Kowalski is a veteran of the investment banking industry, holding numerous senior positions with firms such as Bankers Trust, where he was Vice Chairman of Europe, the Middle East and Africa, Building offices in Russia, Eastern Europe, Turkey and Israel. He was global head of emerging market investment banking for Credit Suisse and CEO of Rose Square Capital an advisory firm with offices in London, Kiev, and Moscow. Mr. Kowalksi was chairman of the largest bank by capital in Russia. Mr. Kowalski is on the board of The Rollicking Crew University of Michigan Endowed Scholarship Fund, Shorts International and a member of the Clinton Global Initiative, Prague Society and Global Panel. Mr. Kowalski holds a BA in Economics from the University of Michigan.

Mr. Zafirelis has more than 25 years of CEO experience in private and public companies, including start-up ventures and turnaround situations. He has an extensive background in the biotech and medical device industries, with broad knowledge of oxygen therapeutic and cardiovascular products. Mr. Zafirelis was part of the original team at Biopure that led the development and approval of Oxyglobin®, the veterinary oxygen carrier, by the FDA and EMA. He has led two cardiac device companies, Medquest and Cardiacassist, and has substantial experience in the approval of new biologics and devices with regulators worldwide. Mr. Zafirelis has an MS in Chemistry and an MBA from the University of Southern California.

Mr. Serov has over 20 years of experience in the Investment Banking industry. He spent most of his career in London running such groups as capital markets, structured products, and advisory. Mr. Serov has worked at Bankers Trust, Rose Square Capital, Dresdner Kleinwort Benson, and Renaissance Capital. Before joining Hemoglobin Oxygen Therapeutics, he was heading up coverage for corporate clients and financial institutions at Sberbank, the largest Russian bank. Mr. Serov has a BA in Mathematics and Economics from Connecticut College.

Mr. Leibensperger has 18 years of experience in Biopharmaceutical Manufacturing and Operations Management. He was an original team member with Biopure Corp. that helped bring Oxyglobin® and Hemopure® production to full scale and an integral part of achieving FDA and EMA GMP approval for manufacturing facilities. Bruce has had direct responsibilities for addressing FDA, EMA, and MHRA regulatory agencies. Most recently served as a Plant Director at OPK Biotech LLC and was responsible for restart operations. Employing Lean Manufacturing principles, the OPK Biotech Souderton Facility was fully operational ahead of schedule and gained VMD approval for veterinary product marketing. Previously, he served as a Biomaterials Manufacturing Manager at Globus Medical Inc. where he managed restructuring of department personnel and multiple production lines including polymer-based bone void implants, and spinal implant devices that gained both FDA and EU marketing approval. Mr. Leibensperger has a B.S. degree in Biology from Susquehanna University.

Brian Dawson has over 25 years experience working with the development and commercialization of Hemopure and Oxyglobin. In this position with Hemoglobin Oxygen Therapeutics LLC, Mr. Dawson is responsible for the transition of the manufacturing process and components from the Cambridge, MA manufacturing facility to the Souderton, PA manufacturing facility. Mr. Dawson started his career with Biopure in 1989 and held several positions in manufacturing operations offering broad qualifications in all facets of production, maintenance, calibration, supply chain, process engineering, validation, environmental control, anaerobic aseptic filling, packaging, microbiology and capacity management. The scope of Mr. Dawson’s experience encompasses preclinical research and development phase through product approval and marketing. He is successful in streamlining production processes, accelerating performance, reducing costs, and meeting time-critical industry demands. Brian was Director of Operations for both Biopure and OPK Biotech LLC, and has a BA from North Adams State College (Massachusetts College of Liberal Arts).

Manufacturing

Source of hemoglobin and viral safety

Hemopure and Oxyglobin are sourced from bovine red blood cells (RBCs). The Hemoglobin (Hb) found in RBCs is extracted, purified and chemically cross-linked (polymerized) for stability, and formulated in a Lactated Ringer's Solution.

Our quality management system includes a comprehensive herd management program to ensure the safety of all raw material used in production. All sourced cattle are born in the USA or Canada and obtained from pre-qualified suppliers that maintain comprehensive health and feed histories for each animal. All collected material is held in quarantine until a post mortem inspection of the cattle is conducted by the onsite USDA veterinarian, and released for human consumption.

Additionally, our products hold certificates of suitability (CEP) for TSE from the European Directorate for the Quality of Medicines & Healthcare (EDQM) that certifies compliance with the European Pharmacopoeia general chapter 5.2.8 ‘Minimizing the risk of transmitting animal spongiform encephalopathy agents via medicinal products'.

Manufacturing process

Our products are manufactured by an extensive purification procedure. The purification of hemoglobin involves an automated state-of- the-art process consisting of multiple separation and filtration steps including specific hemoglobin isolation by large-scale, high-pressure ion exchange liquid chromatography. During the manufacturing process hemoglobin is crosslinked and polymerized by reaction with glutaraldehyde under totally automated procedures. We have recently consolidated all manufacturing activities at our site in Souderton PA, where the facility is undergoing a multimillion dollar expansion to accommodate increased capacity for all production steps from collection of starting materials through aseptic fill finish.

Oxygen carrying solutions

Why an oxygen carrying solution?

Oxygen is indispensable to the life of all human tissues. Hemoglobin, a protein normally contained within red blood cells (RBCs), carries and releases oxygen to the body’s tissues. Medical conditions such as ischemia or anemia can compromise tissue oxygenation. Ischemia is a decrease or lack of RBC flow to an organ or body part due to obstructed or constricted blood vessels, as in heart attack, stroke and certain medical procedures. Anemia is a deficiency of RBCs or hemoglobin associated with blood loss (e.g., from injury or surgery) or other disorders. Oxygen deprivation, even for several minutes, can result in cell damage, organ dysfunction and, if prolonged, death.

The most critical property of each product is an ability to efficiently transport oxygen. There are two mechanisms by which oxygen transport is enhanced. Promoting both convective and diffusive oxygen delivery; the net result is an increase in oxygen delivery due to both an increase in the oxygen-carrying capacity of the plasma, and changes in the rheology of blood. HBOC-201 has a viscosity of 1.3 centipoise, about 1/3 of that of blood. Addition of HBOC-201 to blood decreases the overall viscosity. The products increase plasma and total hemoglobin concentration and thus increases arterial oxygen content.

Research areas

Our priority is the clinical development of Hemopure, (i) as a perfusion fluid in organ transplantation, (ii) Oxygen carrying support in severe anemia where blood is not an option and (iii) for ischemia/infarct reduction in patients with large anterior wall myocardial infarctions.

Hemopure

Hemopure is universally compatible and requires no type or cross match prior to intravenous administration through a standard infusion set. Supplied in sterile IV infusion bags, the product is ready to be administered. No reconstitution or other preparation is required. Hemopure also does not need refrigeration and remains stable at room temperature for at least three years.

Normal blood flow

Anemic blood flow

Published Literature

Hemopure and Oxyglobin have to date been the topic of over 200 peer reviewed journal articles, conference proceeding and posters

The following reference list includes many of those, but is by no means all inclusive. The references are date ordered with the most recent first:

2017

Nigam S, McCarron R, Arnaud F. Drug Deliv Transl Res. 2017 Jul 25. doi: 10.1007/s13346-017-0411-6. [Epub ahead of print]

Storage of nitroglycerin (NTG) admixed with HBOC-201 for 30 days in polyolefin plastic bags: a pilot study.

Show more

2017

Keipert PE. Adv Exp Med Biol. 2017;977:343-350. doi: 10.1007/978-3-319-55231-6_45.

Hemoglobin-Based Oxygen Carrier (HBOC) Development in Trauma: Previous Regulatory Challenges, Lessons Learned, and a Path Forward.

2017

Laing RW, Bhogal RH, Wallace L, Boteon Y, Neil DAH, Smith A, Stephenson BTF, Schlegel A, Hübscher SG, Mirza DF, Afford SC, Mergental H. Transplantation. 2017 Nov;101(11):2746-2756. doi: 10.1097/TP.0000000000001821.

The Use of an Acellular Oxygen Carrier in a Human Liver Model of Normothermic Machine Perfusion.

2017

Gomez MF, Aljure O, Ciancio G, Lynn M. Am J Transplant. 2017 Jul;17(7):1941-1944. doi: 10.1111/ajt.14226. Epub 2017 Mar 17.

Hemoglobin-Based Oxygen Carrier Rescues Double-Transplant Patient From Life-Threatening Anemia.

2017

García-Ruiz JM, Galán-Arriola C, Fernández-Jiménez R, Aguero J, Sánchez-González J, García-Alvarez A, Nuno-Ayala M, Dubé GP, Zafirelis Z, López-Martín GJ, Bernal JA, Lara-Pezzi E, Fuster V, Ibáñez B. Basic Res Cardiol. 2017 Mar;112(2):17. doi: 10.1007/s00395-017-0605-6. Epub 2017 Feb 10.

Bloodless reperfusion with the oxygen carrier HBOC-201 in acute myocardial infarction: a novel platform for cardioprotective probes delivery.

2017

Taverne YJ, de Wijs-Meijler D, Te Lintel Hekkert M, Moon-Massat PF, Dubé GP, Duncker DJ, Merkus D. J Appl Physiol (1985). 2017 May 1;122(5):1227-1237. doi: 10.1152/japplphysiol.00677.2016. Epub 2017 Feb 9.

Normalization of hemoglobin-based oxygen carrier-201 induced vasoconstriction: targeting nitric oxide and endothelin.

2016

Mer M, Hodgson E, Wallis L, Jacobson B, Levien L, Snyman J, Sussman MJ, James M, van Gelder A, Allgaier R, Jahr JS. Transfusion. 2016 Oct;56(10):2631-2636. doi: 10.1111/trf.13726. Epub 2016 Sep 23.

Hemoglobin glutamer-250 (bovine) in South Africa: consensus usage guidelines from clinician experts who have treated patients.

2016

Epperla N, Strouse C, VanSandt AM, Foy P. Transfusion. 2016 Jul;56(7):1801-6. doi: 10.1111/trf.13607. Epub 2016 Apr 6.

Difficult to swallow: warm autoimmune hemolytic anemia in a Jehovah's Witness treated with hemoglobin concentrate complicated by achalasia.

2017

Arnaud F, Higgins A, McCarron R, Moon-Massat PF. Artif Cells Nanomed Biotechnol. 2017 Feb;45(1):58-62. Epub 2016 Mar 2.

Determination of methemoglobin and hemoglobin levels in small volume samples.

2015

Holson JF, Stump DG, Pearce LB, Watson RE, DeSesso JM. Reprod Toxicol. 2015 Apr;52:101-7. doi: 10.1016/j.reprotox.2015.01.006. Epub 2015 Feb 16.

Absence of developmental toxicity in a canine model after infusion of a hemoglobin-based oxygen carrier: Implications for risk assessment.

2015

Stump DG, Holson JF, Harris C, Pearce LB, Watson RE, DeSesso JM. Reprod Toxicol. 2015 Apr;52:108-17. doi: 10.1016/j.reprotox.2015.01.005. Epub 2015 Jan 21.

Developmental toxicity in rats of a hemoglobin-based oxygen carrier results from impeded function of the inverted visceral yolk sac.

2014

Weiskopf RB. Anesth Analg. 2014 Oct;119(4):758-60. doi: 10.1213/ANE.0000000000000401.

Hemoglobin-based oxygen carriers: disclosed history and the way ahead: the relativity of safety.

2014

Song BK, Nugent WH, Moon-Massat PF, Pittman RN. Microvasc Res. 2014 Sep;95:124-30. doi: 10.1016/j.mvr.2014.07.005. Epub 2014 Jul 18.

Effects of a hemoglobin-based oxygen carrier (HBOC-201) and derivatives with altered oxygen affinity and viscosity on systemic and microcirculatory variables in a top-load rat model.

2014

Van Hemelrijck J, Levien LJ, Veeckman L, Pitman A, Zafirelis Z, Standl T. Anesth Analg. 2014 Oct;119(4):766-76. doi: 10.1213/ANE.0000000000000305.

A safety and efficacy evaluation of hemoglobin-based oxygen carrier HBOC-201 in a randomized, multicenter red blood cell controlled trial in noncardiac surgery patients.

2014

Lundy JB, Lewis CJ, Cancio LC, Cap AP. Int J Burns Trauma. 2014 Feb 22;4(1):45-8. eCollection 2014.

Experience with the use of Hemopure in the care of a massively burned adult.

2014

Rivera-Chávez FA, Lu A, Liu MM, Abdalla A, Minei JP. J Invest Surg. 2014 Feb;27(1):14-20. doi: 10.3109/08941939.2013.826756.

Hypertonic HBOC-201 decreases neutrophil activation after hemorrhagic shock.

2014

Ortiz D, Barros M, Yan S, Cabrales P. Am J Emerg Med. 2014 Mar;32(3):248-55. doi: 10.1016/j.ajem.2013.11.045. Epub 2013 Dec 7.

Resuscitation from hemorrhagic shock using polymerized hemoglobin compared to blood.

2013

Abutarboush R, Scultetus A, Pappas G, Arnaud F, Auker C, McCarron R, Moon-Massat PF. Curr Drug Discov Technol. 2013 Dec;10(4):315-24.

Effects of N-acetyl-L-cysteine and hyaluronic acid on HBOC-201-induced systemic and cerebral vasoconstriction in the rat.

2013

Galvagno SM Jr, Mackenzie CF. Anesthesiol Clin. 2013 Mar;31(1):1-19. doi: 10.1016/j.anclin.2012.10.004. Epub 2012 Dec 6. Review.

New and future resuscitation fluids for trauma patients using hemoglobin and hypertonic saline.

2013

Jordan SD, Alexander E. J Pharm Pract. 2013 Jun;26(3):257-60. doi: 10.1177/0897190012451928. Epub 2012 Aug 6.

Bovine hemoglobin: a nontraditional approach to the management of acute anemia in a Jehovah's Witness patient with autoimmune hemolytic anemia.

2012

Arnaud F, Scultetus AH, Haque A, Saha B, Kim B, Auker C, Moon-Massat P, McCarron R, Freilich D. Resuscitation. 2012 Aug;83(8):1038-45. doi: 10.1016/j.resuscitation.2012.01.018. Epub 2012 Jan 28.

Sodium nitroprusside ameliorates systemic but not pulmonary HBOC-201-induced vasoconstriction: an exploratory study in a swine controlled haemorrhage model.

2011

Donati F, Mazzarino M, de la Torre X, Botrè F, Islam N, Cowan D. Electrophoresis. 2011 Oct;32(20):2915-8. doi: 10.1002/elps.201100178. Epub 2011 Sep 16.

A simple and rapid pre-confirmation method to distinguish endogenous human haemoglobin from synthetic haemoglobin-based oxygen carriers in doping control.

2011

Auker CR, McCarron RM. J Trauma. 2011 May;70(5 Suppl):S40-1. doi: 10.1097/TA.0b013e31821a5a1e. Review.

US Navy experience with research on, and development of, hemoglobin-based oxygen carriers.

2011

Minei JP. J Trauma. 2011 May;70(5 Suppl):S38-9. doi: 10.1097/TA.0b013e31821a5a09. Review.

Is there a role for hemopure in the prehospital setting?

2012

Haque A, Arnaud F, Teranishi K, Okada T, Kim B, Moon-Massat PF, Auker C, McCarron R, Freilich D, Scultetus AH. Artif Cells Blood Substit Immobil Biotechnol. 2012 Feb;40(1-2):44-55. doi: 10.3109/10731199.2011.585615. Epub 2011 Aug 2.

Pre-hospital resuscitation with HBOC-201 and rFVIIa compared to HBOC-201 alone in uncontrolled hemorrhagic shock in swine.

2012

Jahr JS, Akha AS, Holtby RJ. Curr Drug Discov Technol. 2012 Sep;9(3):158-65. Review.

Crosslinked, polymerized, and PEG-conjugated hemoglobin-based oxygen carriers: clinical safety and efficacy of recent and current products.

2011

McNeil JD, Propper B, Walker J, Holguin L, Evans L, Lee K, Fox PT, Michalek JE, Baisden CE. J Thorac Cardiovasc Surg. 2011 Aug;142(2):411-7. doi: 10.1016/j.jtcvs.2010.11.017.

A bovine hemoglobin-based oxygen carrier as pump prime for cardiopulmonary bypass: reduced systemic lactic acidosis and improved cerebral oxygen metabolism during low flow in a porcine model.

2011

Fitzgerald MC, Chan JY, Ross AW, Liew SM, Butt WW, Baguley D, Salem HH, Russ MK, Deasy C, Martin KE, Mathew JK, Rosenfeld JV. Med J Aust. 2011 May 2;194(9):471-3.

A synthetic haemoglobin-based oxygen carrier and the reversal of cardiac hypoxia secondary to severe anaemia following trauma.

2011

Muir WW, Ilangovan G, Zweier JL, Moon-Massat PF, Rentko VT. Shock. 2011 Jun;35(6):597-603. doi: 10.1097/SHK.0b013e31821366f6.

Vital organ tissue oxygenation after serial normovolemic exchange transfusion with HBOC-201 in anesthetized swine.

2011

Arnaud F, McCarron R, Freilich D. Artif Cells Blood Substit Immobil Biotechnol. 2011 Jun;39(3):155-61. doi: 10.3109/10731199.2010.516260. Epub 2010 Dec 21.

Amylase and lipase detection in hemorrhaged animals treated with HBOC-201.

2011

Arnaud F, Scultetus AH, Kim B, Haque A, Saha B, Nigam S, Moon-Massat P, Auker C, McCarron R, Freilich D. Artif Cells Blood Substit Immobil Biotechnol. 2011 Aug;39(4):195-205. doi: 10.3109/10731199.2010.533126. Epub 2010 Dec 6.

Dose response of sodium nitrite on vasoactivity associated with HBOC-201 in a swine model of controlled hemorrhage.

2010

Greenburg AG, Light WR, Dubé GP. Transfusion. 2010 Dec;50(12):2764-7; author reply 2767. doi: 10.1111/j.1537-2995.2010.02814.x.

Reconstructing hemoglobin-based oxygen carriers.

2012

Moon-Massat P, Scultetus A, Arnaud F, Brown A, Haque A, Saha B, Kim B, Sagini E, McGwin G Jr, Auker C, McCarron R, Freilich D. Injury. 2012 May;43(5):638-47. doi: 10.1016/j.injury.2010.10.013. Epub 2010 Nov 20.

The effect HBOC-201 and sodium nitrite resuscitation after uncontrolled haemorrhagic shock in swine.

2012

Teranishi K, Scultetus A, Haque A, Stern S, Philbin N, Rice J, Johnson T, Auker C, McCarron R, Freilich D, Arnaud F. Injury. 2012 May;43(5):585-93. doi: 10.1016/j.injury.2010.09.042. Epub 2010 Oct 30.

Traumatic brain injury and severe uncontrolled haemorrhage with short delay pre-hospital resuscitation in a swine model.

2011

Scultetus A, Arnaud F, Kaplan L, Shander A, Philbin N, Rice J, McCarron R, Freilich D. Artif Cells Blood Substit Immobil Biotechnol. 2011 Apr;39(2):59-68. doi: 10.3109/10731199.2010.501755. Epub 2010 Jul 20.

Hemoglobin-based oxygen carrier (HBOC-201) and escalating doses of recombinant factor VIIa (rFVIIa) as a novel pre-hospital resuscitation fluid in a swine model of severe uncontrolled hemorrhage.

2010

Donahue LL, Shapira I, Shander A, Kolitz J, Allen S, Greenburg G. Transfusion. 2010 Jul;50(7):1561-7. doi: 10.1111/j.1537-2995.2010.02603.x. Epub 2010 Apr 23. Review.

Management of acute anemia in a Jehovah's Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin-based oxygen carrier: a case report and review of literature.

2010

Weiskopf RB. Anesth Analg. 2010 Mar 1;110(3):659-62. doi: 10.1213/ANE.0b013e3181c85255.

Hemoglobin-based oxygen carriers: compassionate use and compassionate clinical trials.

2010

Katz LM, Manning JE, McCurdy S, Sproule C, McGwin G Jr, Moon-Massat P, Cairns CB, Freilich D. Resuscitation. 2010 Apr;81(4):481-7. doi: 10.1016/j.resuscitation.2009.12.015. Epub 2010 Jan 18.

Nitroglycerin attenuates vasoconstriction of HBOC-201 during hemorrhagic shock resuscitation.

2010

Te Lintel Hekkert M, Dubé GP, Regar E, de Boer M, Vranckx P, van der Giessen WJ, Serruys PW, Duncker DJ. Am J Physiol Heart Circ Physiol. 2010 Mar;298(3):H1103-13. doi: 10.1152/ajpheart.00667.2009. Epub 2010 Jan 8.

Preoxygenated hemoglobin-based oxygen carrier HBOC-201 annihilates myocardial ischemia during brief coronary artery occlusion in pigs.

2010

Mackenzie CF, Moon-Massat PF, Shander A, Javidroozi M, Greenburg AG. Anesth Analg. 2010 Mar 1;110(3):685-93. doi: 10.1213/ANE.0b013e3181cd473b.

When blood is not an option: factors affecting survival after the use of a hemoglobin-based oxygen carrier in 54 patients with life-threatening anemia.

2010

Fonseca V, Avizinis J, Moon-Massat P, Freilich D, Kim HW, Hai CM. Vascul Pharmacol. 2010 May-Jun;52(5-6):215-23. doi: 10.1016/j.vph.2009.12.005. Epub 2009 Dec 22.

Differential sensitivities of pulmonary and coronary arteries to hemoglobin-based oxygen carriers and nitrovasodilators: study in a bovine ex vivo model of vascular strips.

2010

Tomori T, Hupalo D, Teranishi K, Michaud S, Hammett M, Freilich D, McCarron R, Arnaud F. Blood Coagul Fibrinolysis. 2010 Jan;21(1):20-7. doi: 10.1097/MBC.0b013e32833113e9.

Evaluation of coagulation stages of hemorrhaged swine: comparison of thromboelastography and rotational elastometry.

2009

Zapletal C, Bode A, Lorenz MW, Gebhard MM, Golling M. Microvasc Res. 2009 Dec;78(3):386-92. doi: 10.1016/j.mvr.2009.08.005. Epub 2009 Aug 26.

Effects of hemodilution with a hemoglobin-based oxygen carrier (HBOC-201) on ischemia/reperfusion injury in a model of partial warm liver ischemia of the rat.

2009

Yu B, Bloch KD, Zapol WM. Trends Cardiovasc Med. 2009 Apr;19(3):103-7. doi: 10.1016/j.tcm.2009.06.004.

Hemoglobin-based red blood cell substitutes and nitric oxide.

2009

Mongan PD, Moon-Massat PF, Rentko V, Mihok S, Dragovich A, Sharma P. J Trauma. 2009 Jul;67(1):51-60. doi: 10.1097/TA.0b013e3181838030.

Regional blood flow after serial normovolemic exchange transfusion with HBOC-201 (Hemopure) in anesthetized swine.

2009

Rodriguez C, Vitturi DA, He J, Vandromme M, Brandon A, Hutchings A, Rue LW 3rd, Kerby JD, Patel RP. Biochem J. 2009 Aug 27;422(3):423-32. doi: 10.1042/BJ20090735.

Sodium nitrite therapy attenuates the hypertensive effects of HBOC-201 via nitrite reduction.

2009

Marinaro J, Smith J, Tawil I, Billstrand M, Crookston KP. Transfusion. 2009 Oct;49(10):2054-9. doi: 10.1111/j.1537-2995.2009.02235.x. Epub 2009 May 27. Review.

HBOC-201 use in traumatic brain injury: case report and review of literature.

2009

Muller CF. S Afr Med J. 2009 Feb;99(2):72, 74; author reply 74.

Blood alternative products: correction regarding Jehovah's Witnesses.

2010

Jahr JS, Liu H, Albert OK, Gull A, Moallempour M, Lim J, Gosselin R. Am J Ther. 2010 Mar-Apr;17(2):140-7. doi: 10.1097/MJT.0b013e3181a2b08d.

Does HBOC-201 (Hemopure) affect platelet function in orthopedic surgery: a single-site analysis from a multicenter study.

2009

Mackenzie CF. Br J Hosp Med (Lond). 2009 Jan;70(1):26-30.

Haemoglobin-based oxygen carriers: is the benefit worth the risk?

2009

Freilich D, Pearce LB, Pitman A, Greenburg G, Berzins M, Bebris L, Ahlers S, McCarron R. J Trauma. 2009 Feb;66(2):365-76. doi: 10.1097/TA.0b013e3181820d5c.

HBOC-201 vasoactivity in a phase III clinical trial in orthopedic surgery subjects--extrapolation of potential risk for acute trauma trials.

2008

Bateman C. S Afr Med J. 2008 Oct;98(10):746, 748.

Metanalysis critical of blood alternative product challenged.

2008

Dubé GP, Vranckx P, Greenburg AG. EuroIntervention. 2008 May;4(1):161-5. Review.

HBOC-201: the multi-purpose oxygen therapeutic.

2008

Meliga E, Vranckx P, Regar E, Kint PP, Duncker DJ, Serruys PW. EuroIntervention. 2008 May;4(1):99-107.

Proof-of-concept trial to evaluate haemoglobin based oxygen therapeutics in elective percutaneous coronary revascularisation. Rationale, protocol design and haemodynamic results.

2009

Yu B, Volpato GP, Chang K, Bloch KD, Zapol WM. Anesthesiology. 2009 Jan;110(1):113-22. doi: 10.1097/ALN.0b013e318190bc4f.

Prevention of the pulmonary vasoconstrictor effects of HBOC-201 in awake lambs by continuously breathing nitric oxide.

2008

Mackenzie CF, Morrison C, Jaberi M, Genuit T, Katamuluwa S, Rodriguez A. J Clin Anesth. 2008 Nov;20(7):538-41. doi: 10.1016/j.jclinane.2008.05.012. Epub 2008 Nov 18.

Management of hemorrhagic shock when blood is not an option.

2008

Arnaud F, Hammett M, Philbin N, Scultetus A, McCarron R, Freilich D. Blood Coagul Fibrinolysis. 2008 Oct;19(7):669-77. doi: 10.1097/MBC.0b013e3283089198.

Hematologic effects of recombinant factor VIIa combined with hemoglobin-based oxygen carrier-201 for prehospital resuscitation of swine with severe uncontrolled hemorrhage due to liver injury.

2008

Fraser JF, Härtl R. Crit Care Med. 2008 Oct;36(10):2951-2. doi: 10.1097/CCM.0b013e31818724f2.

Even in trauma, time is brain.

2008

Levien LJ, Hodgson RE, James MF. JAMA. 2008 Sep 17;300(11):1295; author reply 1298-9. doi: 10.1001/jama.300.11.1295-a.

Hemoglobin-based blood substitutes and risk of myocardial infarction and death.

2008

Dudkiewicz M, Harpaul TA, Proctor KG. Crit Care Med. 2008 Oct;36(10):2838-48. doi: 10.1097/CCM.0b013e318186f6b3.

Hemoglobin-based oxygen carrying compound-201 as salvage therapy for severe neuro- and polytrauma (Injury Severity Score = 27-41).

2008

Pachinburavan M, Marik PE. Clin Transl Sci. 2008 Sep;1(2):172-3. doi: 10.1111/j.1752-8062.2008.00006.x.

Bovine blood and neuromuscular paralysis as a bridge to recovery in a patient with severe autoimmune hemolytic anemia.

2008

Jahr JS, Moallempour M, Lim JC. Expert Opin Biol Ther. 2008 Sep;8(9):1425-33. doi: 10.1517/14712598.8.9.1425 . Review.

HBOC-201, hemoglobin glutamer-250 (bovine), Hemopure (Biopure Corporation).

2008

Malkevich NV, Dong F, Vandermolen CA, Philbin NB, Rice JP, Scultetus A, Hong J, Arnaud F, Hall CH, McGwin G Jr, Pearce LB, Handrigan M, Ahlers S, McCarron RM, Freilich D. J Trauma. 2008 Jun;64(6):1498-510. doi: 10.1097/TA.0b013e3181454a05.

Innate immune response after resuscitation with hemoglobin-based oxygen carrier and recombinant factor VIIA in uncontrolled hemorrhagic shock in a swine model.

2008

Jahr JS, Mackenzie C, Pearce LB, Pitman A, Greenburg AG. J Trauma. 2008 Jun;64(6):1484-97. doi: 10.1097/TA.0b013e318173a93f.

HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery.

2009

Stern S, Rice J, Philbin N, McGwin G, Arnaud F, Johnson T, Flournoy WS, Ahlers S, Pearce LB, McCarron R, Freilich D. Shock. 2009 Jan;31(1):64-79. doi: 10.1097/SHK.0b013e3181778dc3.

Resuscitation with the hemoglobin-based oxygen carrier, HBOC-201, in a swine model of severe uncontrolled hemorrhage and traumatic brain injury.

2008

Kocian R, Spahn DR. Best Pract Res Clin Anaesthesiol. 2008 Mar;22(1):63-80. Review.

Haemoglobin, oxygen carriers and perioperative organ perfusion.

2008

Rice J, Philbin N, Light R, Arnaud F, Steinbach T, McGwin G, Collier S, Malkevich N, Moon-Massatt P, Rentko V, Pearce LB, Ahlers S, McCarron R, Handrigan M, Freilich D. J Trauma. 2008 May;64(5):1240-57. doi: 10.1097/TA.0b013e318058245e.

The effects of decreasing low-molecular weight hemoglobin components of hemoglobin-based oxygen carriers in swine with hemorrhagic shock.

2008

Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. JAMA. 2008 May 21;299(19):2304-12. doi: 10.1001/jama.299.19.jrv80007. Epub 2008 Apr 28. Erratum in: JAMA. 2008 Sep 17;300(11): 1300.

Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis.

2008

Yu B, Raher MJ, Volpato GP, Bloch KD, Ichinose F, Zapol WM. Circulation. 2008 Apr 15;117(15):1982-90. doi: 10.1161/CIRCULATIONAHA.107.729137. Epub 2008 Apr 7.

Inhaled nitric oxide enables artificial blood transfusion without hypertension.

2008

Rosenthal G, Morabito D, Cohen M, Roeytenberg A, Derugin N, Panter SS, Knudson MM, Manley G. J Neurosurg. 2008 Mar;108(3):575-87. doi: 10.3171/JNS/2008/108/3/0575.

Use of hemoglobin-based oxygen-carrying solution-201 to improve resuscitation parameters and prevent secondary brain injury in a swine model of traumatic brain injury and hemorrhage: laboratory investigation.

2008

Serruys PW, Vranckx P, Slagboom T, Regar E, Meliga E, de Winter RJ, Heyndrickx G, Schuler G, van Remortel EA, Dubé GP, Symons J. EuroIntervention. 2008 Mar;3(5):600-9.

Haemodynamic effects, safety, and tolerability of haemoglobin-based oxygen carrier-201 in patients undergoing PCI for CAD.

2008

Buehler PW, Alayash AI. Biochim Biophys Acta. 2008 Oct;1784(10):1378-81. doi: 10.1016/j.bbapap.2007.12.009. Epub 2008 Jan 3. Review.

All hemoglobin-based oxygen carriers are not created equally.

2008

Moon-Massat PF, Tierney JP, Hock KG, Scott MG. Clin Biochem. 2008 Apr;41(6):432-5. doi: 10.1016/j.clinbiochem.2007.12.003. Epub 2007 Dec 23.

Hitachi Hemolytic Index correlates with HBOC-201 concentrations: impact on suppression of analyte results.

2007

Rivera-Chavez FA, Huerta S, Brown R, York GB, Minei JP. J Trauma. 2007 Nov;63(5):1113-9.

Resuscitation from hemorrhagic shock comparing standard hemoglobin-based oxygen carrier (HBOC)-201 versus 7.5% hypertonic HBOC-201.

2007

Arnaud F, Fasipe D, Philbin N, Rice J, Flournoy WS, Ahlers S, McCarron R, Freilich D. Transfusion. 2007 Nov;47(11):2098-109.

Hematology patterns after hemoglobin-based oxygen carrier resuscitation from severe controlled hemorrhage with prolonged delayed definitive care.

2007

VanderMolen C, Malkevich N, Philbin N, Rice J, Collier S, Hall C, Ahlers S, McCarron R, Freilich D, McGwin G, Pearce LB. Artif Cells Blood Substit Immobil Biotechnol. 2007;35(5):507-17.

Immune effects of decreasing low-molecular weight hemoglobin components of hemoglobin-based oxygen carriers (HBOC) in a swine model of severe controlled hemorrhagic shock.

2007

Wang TY, Rao SV. Am J Cardiovasc Drugs. 2007;7(4):225-33. Review.

Anemia in patients undergoing percutaneous coronary intervention: current issues and future directions.

2007

Jahr JS, Walker V, Manoochehri K. Curr Opin Anaesthesiol. 2007 Aug;20(4):325-30. Review.

Blood substitutes as pharmacotherapies in clinical practice.

2007

Stefan DC, Uys R, Wessels G. Pediatr Hematol Oncol. 2007 Jun;24(4):269-73.

Hemopure transfusion in a child with severe anemia.

2007

Hall C, Malkevich N, Handrigan M, Vandermolen C, Aranaud F, Hong J, Dong F, Rice J, Philbin N, Ahlers S, McCarron R, Freilich D, McGwin G, Flournoy WS, Pearce LB. Artif Cells Blood Substit Immobil Biotechnol. 2007;35(3):259-74.

Innate immune responses in Swine resuscitated from severe traumatic hemorrhagic shock with hemoglobin-based oxygen carrier-201.

2007

Dimino ML, Palmer AF. Biotechnol Prog. 2007 Jul-Aug;23(4):921-31. Epub 2007 Jun 8.

Hemoglobin-based O2 carrier O2 affinity and capillary inlet pO2 are important factors that influence O2 transport in a capillary.

2007

Kerby JD, Sainz JG, Zhang F, Hutchings A, Sprague S, Farrokhi FR, Son M. Shock. 2007 Jun;27(6):652-6.

Resuscitation from hemorrhagic shock with HBOC-201 in the setting of traumatic brain injury.

2007

Philbin N, Handrigan M, Rice J, McNickle K, McGwin G, Williams R, Warndorf M, Arnaud F, Malkevich N, McCarron R, Freilich D. Resuscitation. 2007 Aug;74(2):332-43. Epub 2007 Mar 23.

Resuscitation following severe, controlled hemorrhage associated with a 24 h delay to surgical intervention in swine using a hemoglobin based oxygen carrier as an oxygen bridge to definitive care.

2007

Hamilton RG, Kickler TS. Transfusion. 2007 Apr;47(4):723-8.

Bovine hemoglobin (glutamer-250, Hemopure)-specific immunoglobulin G antibody cross-reacts with human hemoglobin but does not lyse red blood cells in vitro.

2006

Rice J, Philbin N, Handrigan M, Hall C, McGwin G, Ahlers S, Pearce LB, Arnaud F, McCarron R, Freilich D. J Trauma. 2006 Nov;61(5):1085-99.

Vasoactivity of bovine polymerized hemoglobin (HBOC-201) in swine with traumatic hemorrhagic shock with and without brain injury.

2007

Ashenden MJ, Schumacher YO, Sharpe K, Varlet-Marie E, Audran M. Int J Sports Med. 2007 May;28(5):381-5. Epub 2006 Oct 6.

Effects of Hemopure on maximal oxygen uptake and endurance performance in healthy humans.

2003

Mosa MM, Cheng DC. Curr Opin Anaesthesiol. 2003 Feb;16(1):21-6.

Oxygen therapeutics (blood substitutes) in cardiac surgery.

2006

Rice J, Philbin N, McGwin G, Arnaud F, Johnson T, Flournoy WS, Pearce LB, McCarron R, Kaplan L, Handrigan M, Freilich D. Shock. 2006 Sep;26(3):302-10.

Bovine polymerized hemoglobin versus Hextend resuscitation in a swine model of severe controlled hemorrhagic shock with delay to definitive care.

2006

Arnaud F, Handrigan M, Hammett M, Philbin N, Rice J, Dong F, Pearce LB, McCarron R, Freilich D. Transfus Med. 2006 Aug;16(4):290-302.

Coagulation patterns following haemoglobin-based oxygen carrier resuscitation in severe uncontrolled haemorrhagic shock in swine.

2006

Baylis C. Transfusion. 2006 Jul;46(7):1104-11.

Acute and long-term effects of modified hemoglobin (HBOC-201) in a rat model of hypertension and chronic kidney disease.

2006

Kaplan LJ, Philbin N, Arnaud F, Rice J, Dong F, Freilich D. J Trauma. 2006 Jul;61(1):90-7; discussion 97-8.

Resuscitation from hemorrhagic shock: fluid selection and infusion strategy drives unmeasured ion genesis.

2006

Patel MB, Feinstein AJ, Saenz AD, Majetschak M, Proctor KG. J Trauma. 2006 Jul;61(1):46-56.

Prehospital HBOC-201 after traumatic brain injury and hemorrhagic shock in swine.

2006

Estrada RR. Mil Med. 2006 May;171(5):381-8.

Are i-STAT results adversely affected by an artificial blood substitute in vivo?

2006

Tsai AG, Cabrales P. Crit Care Med. 2006 May;34(5):1566-7.

Can the effects of vasoactivity of molecular hemoglobin-based plasma expanders be ignored?

2006

George I, Yi GH, Schulman AR, Morrow BT, Cheng Y, Gu A, Zhang G, Oz MC, Burkhoff D, Wang J. Am J Physiol Heart Circ Physiol. 2006 Sep;291(3):H1126-37. Epub 2006 Apr 14.

A polymerized bovine hemoglobin oxygen carrier preserves regional myocardial function and reduces infarct size after acute myocardial ischemia.

2006

Johnson T, Arnaud F, Dong F, Philbin N, Rice J, Asher L, Arrisueno M, Warndorf M, Gurney J, McGwin G, Kaplan L, Flournoy WS, Apple FS, Pearce LB, Ahlers S, McCarron R, Freilich D. Crit Care Med. 2006 May;34(5):1464-74.

Bovine polymerized hemoglobin (hemoglobin-based oxygen carrier-201) resuscitation in three swine models of hemorrhagic shock with militarily relevant delayed evacuation--effects on histopathology and organ function.

2006

Bonegio RG, Fuhro R, Ragno G, Robert Valeri C, Lieberthal W. Artif Cells Blood Substit Immobil Biotechnol. 2006;34(2):145-57.

A comparison of the acute hemodynamic and delayed effects of 50% exchange transfusion with two different cross-linked hemoglobin based oxygen carrying solutions and Pentastarch.

2006

Ortegon DP, Davis MR, Sampson JB, Dick EJ, Kashyap V, Kerby JD. Microsurgery. 2006;26(3):203-6.

Bovine hemoglobin-based oxygen-carrying solution (HBOC-201) improves flap survival in a rat model of epigastric flap failure.

2006

Dong F, Hall CH, Golech SA, Philbin NB, Rice JP, Gurney J, Arnaud FG, Hammett M, Ma X, Flournoy WS, Hong J, Kaplan LJ, Pearce LB, McGwin G, Ahlers S, McCarron R, Freilich D. Shock. 2006 Jan;25(1):50-5.

Immune effects of resuscitation with HBOC-201, a hemoglobin-based oxygen carrier, in swine with moderately severe hemorrhagic shock from controlled hemorrhage.

2005

Gottschalk A, Raabe A, Hommel M, Rempf C, Freitag M, Standl T. Artif Cells Blood Substit Immobil Biotechnol. 2005;33(4):379-89.

Influence of the hemoglobin solution HBOC-201 on tissue oxygenation in the rat R1H-tumor.

2005

Fitzpatrick CM, Biggs KL, Atkins BZ, Quance-Fitch FJ, Dixon PS, Savage SA, Jenkins DH, Kerby JD. J Trauma. 2005 Aug;59(2):273-81; discussion 281-3.

Prolonged low-volume resuscitation with HBOC-201 in a large-animal survival model of controlled hemorrhage.

2005

Agrawal YP, Freedman M, Szczepiorkowski ZM. Transfusion. 2005 Nov;45(11):1735-8.

Long-term transfusion of polymerized bovine hemoglobin in a Jehovah's Witness following chemotherapy for myeloid leukemia: a case report.

2005

Raabe A, Gottschalk A, Hommel M, Dubben HH, Strandl T. Strahlenther Onkol. 2005 Nov;181(11):730-7.

No effect of the hemoglobin solution HBOC-201 on the response of the rat R1H tumor to fractionated irradiation.

2005

Freitag M, Standl TG, Gottschalk A, Burmeister MA, Rempf C, Horn EP, Strate T, Schulte Am Esch J. Can J Anaesth. 2005 Nov;52(9):904-14.

Enhanced central organ oxygenation after application of bovine cell-free hemoglobin HBOC-201.

2005

Masuno T, Moore EE, Cheng AM, Moore PK, Grant AR, Johnson JL. Surgery. 2005 Aug;138(2):335-41.

Prehospital hemoglobin-based oxygen carrier resuscitation attenuates postinjury acute lung injury.

2005

Philbin N, Rice J, Gurney J, McGwin G, Arnaud F, Dong F, Johnson T, Flournoy WS, Ahlers S, Pearce LB, McCarron R, Freilich D. Resuscitation. 2005 Sep;66(3):367-78.

A hemoglobin-based oxygen carrier, bovine polymerized hemoglobin (HBOC-201) versus hetastarch (HEX) in a moderate severity hemorrhagic shock swine model with delayed evacuation.

2005

Laccetti A, Bagai J, Gawryl MS, Light WR. Dev Biol (Basel). 2005;120:35-6.

Hemopure's process demonstrates TSE and viral clearance.

2005

Arnaud F, Hammett M, Asher L, Philbin N, Rice J, Dong F, Pearce B, Flournoy WS, Nicholson C, McCarron R, Freilich D. Shock. 2005 Aug;24(2):145-52.

Effects of bovine polymerized hemoglobin on coagulation in controlled hemorrhagic shock in swine.

2005

Burkhoff D, Lefer DJ. Am Heart J. 2005 Apr;149(4):573-9. Review.

Cardioprotection before revascularization in ischemic myocardial injury and the potential role of hemoglobin-based oxygen carriers.

2005

Goebel C, Alma C, Howe C, Kazlauskas R, Trout G. J Chromatogr Sci. 2005 Jan;43(1):39-46.

Methodologies for detection of hemoglobin-based oxygen carriers.

2005

Caswell JE, Strange MB, Rimmer DM 3rd, Gibson MF, Cole P, Lefer DJ. Am J Physiol Heart Circ Physiol. 2005 Apr;288(4):H1796-801.

A novel hemoglobin-based blood substitute protects against myocardial reperfusion injury.

2005

Jahr JS, Osgood S, Rothenberg SJ, Li QL, Butch AW, Gunther R, Cheung A, Driessen B. Anesth Analg. 2005 Feb;100(2):431-6.

Lactate measurement interference by hemoglobin-based oxygen carriers (Oxyglobin, Hemopure, and Hemolink).

2005

Standl T. Anasthesiol Intensivmed Notfallmed Schmerzther. 2005 Jan;40(1):38-45. German.

[Autologous transfusion - from euphoria to reason: clinical practice based on scientific knowledge. (Part IV). Artificial oxygen carriers: cell-free hemoglobin solutions -- current status 2004].

2004

James MF, Potgieter HE, Ellis P. Anesth Analg. 2004 Dec;99(6):1593-7, table of contents.

The effect of hemopure on coagulation in clinically relevant concentrations.

2004

Gurney J, Philbin N, Rice J, Arnaud F, Dong F, Wulster-Radcliffe M, Pearce LB, Kaplan L, McCarron R, Freilich D. J Trauma. 2004 Oct;57(4):726-38.

A hemoglobin based oxygen carrier, bovine polymerized hemoglobin (HBOC-201) versus Hetastarch (HEX) in an uncontrolled liver injury hemorrhagic shock swine model with delayed evacuation.

2004

Fitzpatrick CM, Savage SA, Kerby JD, Clouse WD, Kashyap VS. J Am Coll Surg. 2004 Nov;199(5):693-701.

Resuscitation with a blood substitute causes vasoconstriction without nitric oxide scavenging in a model of arterial hemorrhage.

2004

Bateman C. S Afr Med J. 2004 Sep;94(9):728-9.

Hope for reducing SA's trauma deaths?

2004

Guan F, Uboh CE, Soma LR, Luo Y, Jahr JS, Driessen B. Anal Chem. 2004 Sep 1;76(17):5127-35.

Confirmation and quantification of hemoglobin-based oxygen carriers in equine and human plasma by hyphenated liquid chromatography tandem mass spectrometry.

2004

Guan F, Uboh C, Soma L, Luo Y, Driessen B. Anal Chem. 2004 Sep 1;76(17):5118-26.

Unique tryptic peptides specific for bovine and human hemoglobin in the detection and confirmation of hemoglobin-based oxygen carriers.

2004

Henderson CL, Anderson CM, Sorrells DL, Wilson BJ, Dick EJ, DiGeronimo RJ. Pediatr Crit Care Med. 2004 Jul;5(4):384-90.

The use of a hemoglobin-based oxygen-carrying solution (HBOC-201) for extracorporeal membrane oxygenation in a porcine model with acute respiratory distress syndrome.

2004

Greenburg AG, Kim HW. Crit Care. 2004;8 Suppl 2:S61-4. Epub 2004 Jun 14. Review.

Hemoglobin-based oxygen carriers.

2004

Anbari KK, Garino JP, Mackenzie CF. Eur Spine J. 2004 Oct;13 Suppl 1:S76-82. Epub 2004 May 27. Review.

Hemoglobin substitutes.

2004

Marret E, Bonnin P, Mazoyer E, Riou B, Jacobs T, Coriat P, Samama CM. Anesth Analg. 2004 Mar;98(3):604-10, table of contents.

The effects of a polymerized bovine-derived hemoglobin solution in a rabbit model of arterial thrombosis and bleeding.

2004

Varlet-Marie E, Ashenden M, Lasne F, Sicart MT, Marion B, de Ceaurriz J, Audran M. Clin Chem. 2004 Apr;50(4):723-31. Epub 2004 Feb 5.

Detection of hemoglobin-based oxygen carriers in human serum for doping analysis: confirmation by size-exclusion HPLC.

2002

Schutte AE. Ethics Med. 2002 Summer;18(2):55-62.

Ethical considerations concerning South Africa's approval of a blood substitute.

2003

Lasne F, Crepin N, Ashenden M, Audran M, de Ceaurriz J. Clin Chem. 2004 Feb;50(2):410-5. Epub 2003 Nov 21.

Detection of hemoglobin-based oxygen carriers in human serum for doping analysis: screening by electrophoresis.

2003

La Spina M, Russo G. Minerva Pediatr. 2003 Oct;55(5):483-93, 493-8. Review. English, Italian.

New drugs for childhood anemia.

2003

York GB, Eggers JS, Smith DL, Jenkins DH, McNeil JD, Mueller D, Josephs JD, Kerby JD. J Trauma. 2003 Nov;55(5):873-85.

Low-volume resuscitation with a polymerized bovine hemoglobin-based oxygen-carrying solution (HBOC-201) provides adequate tissue oxygenation for survival in a porcine model of controlled hemorrhage.

2003

Thevis M, Ogorzalek Loo RR, Loo JA, Schänzer W. Anal Chem. 2003 Jul 15;75(14):3287-93.

Doping control analysis of bovine hemoglobin-based oxygen therapeutics in human plasma by LC-electrospray ionization-MS/MS.

2003

Ortegon DP, Dixon PS, Crow KK, Mueller DL, Kerby JD. J Trauma. 2003 Oct;55(4):755-60; discussion 760-1.

The effect of the bovine hemoglobin oxygen therapeutic HBOC-201 on human neutrophil activation in vitro.

2003

Sampson JB, Davis MR, Mueller DL, Kashyap VS, Jenkins DH, Kerby JD. J Trauma. 2003 Oct;55(4):747-54.

A comparison of the hemoglobin-based oxygen carrier HBOC-201 to other low-volume resuscitation fluids in a model of controlled hemorrhagic shock.

2003

Manley GT, Hemphill JC, Morabito D, Erickson V, Holcroft JJ, Derugin N, Knudson MM. Adv Exp Med Biol. 2003;530:311-7.

Small-volume resuscitation with the hemoglobin substitute HBOC-201: effect on brain tissue oxygenation.

2003

Pearce LB, Gawryl MS. Adv Exp Med Biol. 2003;530:261-70.

The pharmacology of tissue oxygenation by biopure's hemoglobin-based oxygen carrier, Hemopure (HBOC-201).

2003

Levy JH. Expert Opin Biol Ther. 2003 Jun;3(3):509-17. Review. Erratum in: Expert Opin Biol Ther. 2003 Sep;3(6):1017.

The use of haemoglobin glutamer-250 (HBOC-201) as an oxygen bridge in patients with acute anaemia associated with surgical blood loss.

2003

Khan AK, Jahr JS, Nesargi S, Rothenberg SJ, Tang Z, Cheung A, Gunther RA, Kost GJ, Driessen B. Anesth Analg. 2003 Jun;96(6):1813-20, table of contents.

Does lead interfere with hemoglobin-based oxygen carrier (HBOC) function? A pilot study of lead concentrations in three approved or tested HBOCs and oxyhemoglobin dissociation with HBOCs and/or bovine blood with varying lead concentrations.

2003

Standl T, Freitag M, Burmeister MA, Horn EP, Wilhelm S, Am Esch JS. J Vasc Surg. 2003 Apr;37(4):859-65.

Hemoglobin-based oxygen carrier HBOC-201 provides higher and faster increase in oxygen tension in skeletal muscle of anemic dogs than do stored red blood cells.

2003

Knudson MM, Lee S, Erickson V, Morabito D, Derugin N, Manley GT. J Trauma. 2003 Feb;54(2):242-52.

Tissue oxygen monitoring during hemorrhagic shock and resuscitation: a comparison of lactated Ringer's solution, hypertonic saline dextran, and HBOC-201.

2003

Jahr JS, Lurie F, Driessen B, Tang Z, Louie RF, Kost G. Am J Ther. 2003 Jan-Feb;10(1):21-8.

Validation of oxygen saturation measurements in a canine model of hemoglobin-based oxygen carrier infusion.

2002

Ortegon DP, Davis MR, Dixon PS, Smith DL, Josephs JD, Mueller DL, Jenkins DH, Kerby JD. J Trauma. 2002 Dec;53(6):1068-72.

The polymerized bovine hemoglobin-based oxygen-carrying solution (HBOC-201) is not toxic to neural cells in culture.

2002

York GB, DiGeronimo RJ, Wilson BJ, Cofer BR, Breuer CK, Josephs JD, Smith DL, Sorrells DL. J Pediatr Surg. 2002 Oct;37(10):1387-92.

Extracorporeal membrane oxygenation in piglets using a polymerized bovine hemoglobin-based oxygen-carrying solution (HBOC-201).

2002

Lee SK, Morabito D, Hemphill JC, Erickson V, Holcroft JJ, Derugin N, Knudson MM, Manley GT. Acad Emerg Med. 2002 Oct;9(10):969-76.

Small-volume resuscitation with HBOC-201: effects on cardiovascular parameters and brain tissue oxygen tension in an out-of-hospital model of hemorrhage in swine.

2002

Lurie F, Jahr JS, Driessen B. Anesth Analg. 2002 Oct;95(4):870-3, table of contents.

The novel HemoCu plasma/low hemoglobin system accurately measures small concentrations of three different hemoglobin-based oxygen carriers in plasma: hemoglobin glutamer-200 (bovine) (Oxyglobin), hemoglobin glutamer-250 (bovine) (Hemopure), and hemoglobin-Raffimer (Hemolink).

2002

Jahr JS, Lurie F, Gosselin R, Lin JS, Wong L, Owings JT, Larkin E. Am J Ther. 2002 Sep-Oct;9(5):431-6.

Effects of hemoglobin glutamer-250 (bovine) (HBOC-201, Hemopure) on coagulation testing.

2002

Gannon CJ, Napolitano LM. Crit Care Med. 2002 Aug;30(8):1893-5.

Severe anemia after gastrointestinal hemorrhage in a Jehovah's Witness: new treatment strategies.

2002

Katz LM, Manning JE, McCurdy S, Pearce LB, Gawryl MS, Wang Y, Brown C; Carolina Resuscitation Research Group.. Resuscitation. 2002 Jul;54(1):77-87.

HBOC-201 improves survival in a swine model of hemorrhagic shock and liver injury.

2002

Levy JH, Goodnough LT, Greilich PE, Parr GV, Stewart RW, Gratz I, Wahr J, Williams J, Comunale ME, Doblar D, Silvay G, Cohen M, Jahr JS, Vlahakes GJ. J Thorac Cardiovasc Surg. 2002 Jul;124(1):35-42.

Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial.

2002

Sprung J, Kindscher JD, Wahr JA, Levy JH, Monk TG, Moritz MW, O'Hara PJ. Anesth Analg. 2002 Apr;94(4):799-808, table of contents.

The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: results of a multicenter, randomized, single-blinded trial.

2002

Jahr JS, Lurie F, Driessen B, Davis JA, Gosselin R, Gunther RA. Can J Anaesth. 2002 Mar;49(3):243-8.

The HemoCue, a point of care B-hemoglobin photometer, measures hemoglobin concentrations accurately when mixed in vitro with canine plasma and three hemoglobin-based oxygen carriers (HBOC).

2001

Arnoldo BD, Minei JP. Curr Opin Crit Care. 2001 Dec;7(6):431-6. Review.

Potential of hemoglobin-based oxygen carriers in trauma patients.

2001

Horn EP, Burmeister MA. Anasthesiol Intensivmed Notfallmed Schmerzther. 2001 Nov;36 Suppl 2:S117-8.

Bovine hemoglobin (HBOC-201) restores tissue oxygen tension during peripheral and coronary artery stenosis under extended hemodilution.

2001

Standl T. Expert Opin Biol Ther. 2001 Sep;1(5):831-43. Review.

Haemoglobin-based erythrocyte transfusion substitutes.

2001

Manning JE, Katz LM, Pearce LB, Batson DN, McCurdy SL, Gawryl MS, Baker CC. Crit Care Med. 2001 Nov;29(11):2067-74.

Selective aortic arch perfusion with hemoglobin-based oxygen carrier-201 for resuscitation from exsanguinating cardiac arrest in swine.

2000

Jahr JS, Lurie F, Gosselin R, Lin JS, Wong L, Larkin E. Clin Lab Sci. 2000 Fall;13(4):210-4.

Effects of a hemoglobin-based oxygen carrier (HBOC-201) on coagulation testing.

2001

Chan FP, Jahr JS, Driessen B, Daunt DA, Li KC. Acad Radiol. 2001 Jul;8(7):583-90.

Validation of in vivo MR measurement of oxygen saturation after resuscitation with a hemoglobin-based oxygen carrier in a rabbit model.

2001

McNeil CJ, Smith LD, Jenkins LD, York MG, Josephs MJ. J Trauma. 2001 Jun;50(6):1063-75.

Hypotensive resuscitation using a polymerized bovine hemoglobin-based oxygen-carrying solution (HBOC-201) leads to reversal of anaerobic metabolism.

2001

Sprung J, Popp H, O'Hara P, Woletz J. Anesth Analg. 2001 Jun;92(6):1413-5.

The successful use of hemoglobin-based oxygen carrier as a primary blood substitute during abdominal aneurysm repair with large blood loss.

2001

Hamilton RG, Kelly N, Gawryl MS, Rentko VT. Transfusion. 2001 Feb;41(2):219-25.

Absence of immunopathology associated with repeated IV administration of bovine Hb-based oxygen carrier in dogs.

2000

Roth RI, Levin J. N Engl J Med. 2000 Oct 26;343(17):1273.

Transfusion of soluble hemoglobin.

2000

Standl T. Infusionsther Transfusionsmed. 2000 May;27(3):128-137.

Arificial Oxygen Carriers as Red Blood Cell Substitutes - Perfluorocarbons and Cell-Free Hemoglobin.

2000

Mullon J, Giacoppe G, Clagett C, McCune D, Dillard T. N Engl J Med. 2000 Jun 1;342(22):1638-43.

Transfusions of polymerized bovine hemoglobin in a patient with severe autoimmune hemolytic anemia.

2000

Manning JE, Katz LM, Brownstein MR, Pearce LB, Gawryl MS, Baker CC. Shock. 2000 Feb;13(2):152-9.

Bovine hemoglobin-based oxygen carrier (HBOC-201) for resuscitation of uncontrolled, exsanguinating liver injury in swine. Carolina Resuscitation Research Group.

2000

LaMuraglia GM, O'Hara PJ, Baker WH, Naslund TC, Norris EJ, Li J, Vandermeersch E. J Vasc Surg. 2000 Feb;31(2):299-308.

The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution.

1999

Hayward R, Lefer AM. Methods Find Exp Clin Pharmacol. 1999 Jul-Aug;21(6):427-33.

Administration of polymerized bovine hemoglobin improves survival in a rat model of traumatic shock.

1999

Wolthuis A, Peek D, Scholten R, Moreira P, Gawryl M, Clark T, Westerhuis L. Clin Chem Lab Med. 1999 Jan;37(1):71-6.

Effect of the hemoglobin-based oxygen carrier HBOC-201 on laboratory instrumentation: cobas integra, chiron blood gas analyzer 840, Sysmex SE-9000 and BCT.

1998

Kasper SM, Grüne F, Walter M, Amr N, Erasmi H, Buzello W. Anesth Analg. 1998 Aug;87(2):284-91.

The effects of increased doses of bovine hemoglobin on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery.

1998

Brauer P, Standl T, Wilhelm S, Burmeister MA, Schulte am Esch J. J Neurosurg Anesthesiol. 1998 Jul;10(3):146-52.

Transcranial Doppler sonography mean flow velocity during infusion of ultrapurified bovine hemoglobin.

1998

Caron A, Menu P, Labrude P, Vigneron C. Artif Cells Blood Substit Immobil Biotechnol. 1998 May;26(3):293-308.

Proposition of a technique to assess the vasoactive effects of hemoglobin-based oxygen carrying solutions in vivo: preliminary results in the rabbit aorta.

1998

Standl T, Burmeister MA, Horn EP, Wilhelm S, Knoefel WT, Schulte am Esch J. Br J Anaesth. 1998 Feb;80(2):189-94.

Bovine haemoglobin-based oxygen carrier for patients undergoing haemodilution before liver resection.

1998

Horn EP, Standl T, Wilhelm S, Jacobs EE, Freitag U, Freitag M, Schulte am Esch J. Anaesthesist. 1998 Feb;47(2):116-23. German.

[Bovine hemoglobin. HBOC-201 causes a reduction of the oxygen partial pressure in poststenotic skeletal muscle].

1997

Standl T, Wilhelm S, Horn EP, Burmeister M, Gundlach M, Schulte am Esch J. Anaesthesist. 1997 Sep;46(9):763-70. German.

[Preoperative hemodilution with bovine hemoglobin. Acute hemodynamic effects in liver surgery patients ].

1997

Sarkozi L, Jacobs E, Clark T, Gawryl MS, Simson E. Clin Chem. 1997 Sep;43(9):1792-4.

Effect of hemoglobin-based oxygen carrier-201 on common chemistry laboratory procedures.

1997

Moreira PL, Lansden CC, Clark TL, Gawryl MS. Clin Chem. 1997 Sep;43(9):1792.

Effect of Hemopure on prothrombin time and activated partial thromboplastin time on seven coagulation analyzers.

1997

Moreira PL, Lansden CC, Clark TL, Gawryl MS. Clin Chem. 1997 Sep;43(9):1790-1.

Effect of Hemopure on the performance of Ektachem and Hitachi clinical analyzers.

1997

Callas DD, Clark TL, Moreira PL, Lansden C, Gawryl MS, Kahn S, Bermes EW Jr. Clin Chem. 1997 Sep;43(9):1744-8.

In vitro effects of a novel hemoglobin-based oxygen carrier on routine chemistry, therapeutic drug, coagulation, hematology, and blood bank assays.

1997

Gonzalez P, Hackney AC, Jones S, Strayhorn D, Hoffman EB, Hughes G, Jacobs EE, Orringer EP. J Investig Med. 1997 Jun;45(5):258-64.

A phase I/II study of polymerized bovine hemoglobin in adult patients with sickle cell disease not in crisis at the time of study.

1997

Wahr JA, Anderson MM, Giacherio DA, Hallock L, Gawryl MS, Lansden C, Tremper KK. J Cardiothorac Vasc Anesth. 1997 Feb;11(1):10-2.

The effects of a blood-salvaging device on blood containing a hemoglobin-based oxygen carrier, HBOC-201.

1997

Waschke KF, Frietsch T, Quintel M, Lenz C, Rebel A. Acta Anaesthesiol Scand Suppl. 1997;111:259-63.

Hemoglobin solutions.

1996

Kasper SM, Walter M, Grüne F, Bischoff A, Erasmi H, Buzello W. Anesth Analg. 1996 Nov;83(5):921-7.

Effects of a hemoglobin-based oxygen carrier (HBOC-201) on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery.

1996

Hughes GS, Francom SF, Antal EJ, Adams WJ, Locker PK, Yancey EP, Jacobs EE. Ann Emerg Med. 1996 Feb;27(2):164-9.

Effects of a novel hemoglobin-based oxygen carrier on percent oxygen saturation as determined with arterial blood gas analysis and pulse oximetry.

1995

Hughes GS Jr, Francome SF, Antal EJ, Adams WJ, Locker PK, Yancey EP, Jacobs EE Jr. J Lab Clin Med. 1995 Nov;126(5):444-51.

Hematologic effects of a novel hemoglobin-based oxygen carrier in normal male and female subjects.

1995

Hughes GS Jr, Yancey EP, Albrecht R, Locker PK, Francom SF, Orringer EP, Antal EJ, Jacobs EE Jr. Clin Pharmacol Ther. 1995 Oct;58(4):434-43.

Hemoglobin-based oxygen carrier preserves submaximal exercise capacity in humans.

2015

Black V, Adamantos S, Barfield D, Tasker S. J Feline Med Surg. 2016 Aug;18(8):597-602. doi: 10.1177/1098612X15588800. Epub 2015 Jun 26.

Feline non-regenerative immune-mediated anaemia: features and outcome in 15 cases.

2015

Raines JA, Storms T. J Zoo Wildl Med. 2015 Mar;46(1):161-3.

A successful transfusion in a tamandua (Tamandua tetradactyla) using both whole blood and blood replacement products.

2014

Peruski AM, Cooper ES, Butler AL. Am J Vet Res. 2014 Jan;75(1):77-84. doi: 10.2460/ajvr.75.1.77.

Microcirculatory effects of a hyperviscous hemoglobin-based solution administered intravenously in dogs with experimentally induced hemorrhagic shock.

2013

Donner MG, Topp SA, Cebula P, Krienen A, Gehrmann T, Sommerfeld A, Reinehr R, Macher A, Herebian D, Mayatepek E, Pannen BH, Knoefel WT, Häussinger D. Biol Chem. 2013 Jan;394(1):97-112. doi: 10.1515/hsz-2012-0153.

HbG200-mediated preinduction of heme oxygenase-1 improves bile flow and ameliorates pericentral downregulation of Bsep and Mrp2 following experimental liver ischemia and reperfusion.

2012

Zhou Y, Cabrales P, Palmer AF. Biophys Chem. 2012 Mar;162:45-60. doi: 10.1016/j.bpc.2011.12.006. Epub 2012 Jan 9.

Simulation of NO and O2 transport facilitated by polymerized hemoglobin solutions in an arteriole that takes into account wall shear stress-induced NO production.

2011

Wehausen CE, Kirby R, Rudloff E. J Am Vet Med Assoc. 2011 Apr 1;238(7):909-14. doi: 10.2460/javma.238.7.909.

Evaluation of the effects of bovine hemoglobin glutamer-200 on systolic arterial blood pressure in hypotensive cats: 44 cases (1997-2008).

2011

Vázquez BY, Hightower CM, Martini J, Messmer C, Frienesenecker B, Corbels P, Tsai AG, Intaglietta M. Crit Care Med. 2011 Jun;39(6):1461-6. doi: 10.1097/CCM.0b013e3182120cdb.

Vasoactive hemoglobin solution improves survival in hemodilution followed by hemorrhagic shock.

2010

Wondratschek C, Weingart C, Kohn B. J Am Anim Hosp Assoc. 2010 Jan-Feb;46(1):12-9.

Primary immune-mediated thrombocytopenia in cats.

2009

Lichtenberger M, Orcutt C, Cray C, Thamm DH, DeBehnke D, Page C, Mull L, Kirby R. J Vet Emerg Crit Care (San Antonio). 2009 Oct;19(5):467-72. doi: 10.1111/j.1476-4431.2009.00465.x.

Comparison of fluid types for resuscitation after acute blood loss in mallard ducks (Anas platyrhynchos).

2009

Lee J, Kim JG, Mahon S, Tromberg BJ, Mukai D, Kreuter K, Saltzman D, Patino R, Goldberg R, Brenner M. J Biomed Opt. 2009 Jul-Aug;14(4):044027. doi: 10.1117/1.3200932.

Broadband diffuse optical spectroscopy assessment of hemorrhage- and hemoglobin-based blood substitute resuscitation.

2009

Rempf C, Standl T, Schenke K, Chammas K, Gottschalk A, Burmeister MA, Gottschalk A. Br J Anaesth. 2009 Oct;103(4):496-504. doi: 10.1093/bja/aep233. Epub 2009 Aug 26.

Administration of bovine polymerized haemoglobin before and during coronary occlusion reduces infarct size in rabbits.

2009

Zambelli AB, Leisewitz AL. J Vet Emerg Crit Care (San Antonio). 2009 Feb;19(1):102-12. doi: 10.1111/j.1476-4431.2009.00386.x.

A prospective, randomized comparison of Oxyglobin (HB-200) and packed red blood cell transfusion for canine babesiosis.

2008

Gundersen SI, Palmer AF. Biotechnol Prog. 2008 Nov-Dec;24(6):1353-64. doi: 10.1002/btpr.56.

Hemoglobin-based oxygen carrier enhanced tumor oxygenation: a novel strategy for cancer therapy.

2009

Singleton CL, Oosterhuis JE, Seibold K, Lamberski N. J Zoo Wildl Med. 2009 Jun;40(2):378-81.

Successful treatment of a southern Pacific rattlesnake (Crotalus viridis helleri) bite in a caracal (Caracal caracal).

2009

Moallempour M, Jahr JS, Lim JC, Weeks D, Butch A, Driessen B. J Cardiothorac Vasc Anesth. 2009 Feb;23(1):41-7. doi: 10.1053/j.jvca.2008.06.006. Epub 2008 Aug 29.

Methemoglobin effects on coagulation: a dose-response study with HBOC-200 (Oxyglobin) in a thrombelastogram model.

2009

Kubulus D, Mathes A, Reus E, Pradarutti S, Pavlidis D, Thierbach JT, Heiser J, Wolf B, Bauer I, Rensing H. Shock. 2009 Aug;32(2):179-89. doi: 10.1097/SHK.0b013e318199352b.

Endothelin-1 contributes to hemoglobin glutamer-200-mediated hepatocellular dysfunction after hemorrhagic shock.

2008

Manalo DJ, Buehler PW, Baek JH, Butt O, D'agnillo F, Alayash AI. Biochem J. 2008 Sep 15;414(3):461-9. doi: 10.1042/BJ20080313.

Acellular haemoglobin attenuates hypoxia-inducible factor-1alpha (HIF-1alpha) and its target genes in haemodiluted rats.

2008

Weingart C, Kohn B. J Feline Med Surg. 2008 Oct;10(5):431-8. doi: 10.1016/j.jfms.2007.10.012. Epub 2008 May 2.

Clinical use of a haemoglobin-based oxygen carrying solution (Oxyglobin) in 48 cats (2002-2006).

2008

Topp SA, Krieg A, Koch A, Tidden CM, Ramp U, Hohlfeld T, Macher A, Schulte am Esch J 2nd, Eisenberger CF, Stoecklein NH, Knoefel WT. J Surg Res. 2008 Dec;150(2):243-54. doi: 10.1016/j.jss.2008.02.033. Epub 2008 Mar 18.

Hemoglobin-glutamer 200 reduces reperfusion injury of the cold preserved rat liver by induction of heme oxygenase-1.

2008

Jahr JS, Lurie F, Bezdikian V, Driessen B, Gunther RA. Am J Ther. 2008 Mar-Apr;15(2):98-101. doi: 10.1097/MJT.0b013e31804c6f98.

Measuring circulating blood volume using infused hemoglobin-based oxygen carrier (oxyglobin) as an indicator: verification in a canine hypovolemia model.

2008

Rempf C, Ritter A, Schrepfer S, Freitag M, Standl T, Gottschalk A. Artif Cells Blood Substit Immobil Biotechnol. 2008;36(1):34-44. doi: 10.1080/10731190701857769.

Failed induction of heme oxygenase 1 in endothelial cells exposed to the hemoglobin based oxygen carrier Oxyglobin.

2008

Jahr JS, Weeks DL, Desai P, Lim JC, Butch AW, Gunther R, Driessen B. J Cardiothorac Vasc Anesth. 2008 Feb;22(1):34-9. doi: 10.1053/j.jvca.2007.02.016. Epub 2007 May 24.

Does OxyVita, a new-generation hemoglobin-based oxygen carrier, or oxyglobin acutely interfere with coagulation compared with normal saline or 6% hetastarch? An ex vivo thromboelastography study.

2007

Driessen B, Zarucco L, Gunther RA, Burns PM, Lamb SV, Vincent SE, Boston RA, Jahr JS, Cheung AT. Crit Care Med. 2007 Sep;35(9):2101-9.

Effects of low-volume hemoglobin glutamer-200 versus normal saline and arginine vasopressin resuscitation on systemic and skeletal muscle blood flow and oxygenation in a canine hemorrhagic shock model.

2006

Driessen B, Jahr JS, Lurie F, Gunther RA. Vet Anaesth Analg. 2006 Nov;33(6):368-80.

Effects of isovolemic resuscitation with hemoglobin-based oxygen carrier Hemoglobin glutamer-200 (bovine) on systemic and mesenteric perfusion and oxygenation in a canine model of hemorrhagic shock: a comparison with 6% hetastarch solution and shed blood.

2006

Cheung AT, Duong PL, Driessen B, Chen PC, Jahr JS, Gunther RA. Clin Hemorheol Microcirc. 2006;34(1-2):325-34.

Systemic function, oxygenation and microvascular correlation during treatment of hemorrhagic shock with blood substitutes.

2006

Freitag M, Standl TG, Kleinhans H, Gottschalk A, Mann O, Rempf C, Bachmann K, Gocht A, Petri S, Izbicki JR, Strate T. Pancreatology. 2006;6(3):232-9. Epub 2006 Mar 9.

Improvement of impaired microcirculation and tissue oxygenation by hemodilution with hydroxyethyl starch plus cell-free hemoglobin in acute porcine pancreatitis.

2005

Buehler PW, Boykins RA, Jia Y, Norris S, Freedberg DI, Alayash AI. Anal Chem. 2005 Jun 1;77(11):3466-78.

Structural and functional characterization of glutaraldehyde-polymerized bovine hemoglobin and its isolated fractions.

2005

Burmeister MA, Rempf C, Standl TG, Rehberg S, Bartsch-Zwemke S, Krause T, Tuszynski S, Gottschalk A, Schulte am Esch J. Br J Anaesth. 2005 Dec;95(6):737-45. Epub 2005 Oct 14.

Effects of prophylactic or therapeutic application of bovine haemoglobin HBOC-200 on ischaemia-reperfusion injury following acute coronary ligature in rats.

2005

King DR, Cohn SM, Proctor KG. J Trauma. 2005 Sep;59(3):553-60; discussion 560-2.

Resuscitation with a hemoglobin-based oxygen carrier after traumatic brain injury.

2005

Soma LR, Uboh CE, Guan F, Luo Y, Moate PJ, Boston RC, Driessen B. Anesth Analg. 2005 Jun;100(6):1570-5.

The pharmacokinetics of hemoglobin-based oxygen carrier hemoglobin glutamer-200 bovine in the horse.

2005

Gasthuys M, Alves S, Tabet JC. Anal Chem. 2005 May 15;77(10):3372-8.

N-terminal adducts of bovine hemoglobin with glutaraldehyde in a hemoglobin-based oxygen carrier.

2005

Strate T, Mann O, Kleinhans H, Rusani S, Schneider C, Yekebas E, Freitag M, Standl T, Bloechle C, Izbicki JR. Pancreas. 2005 Apr;30(3):254-9.

Microcirculatory function and tissue damage is improved after therapeutic injection of bovine hemoglobin in severe acute rodent pancreatitis.

2005

Osgood SL, Jahr JS, Desai P, Tsukamoto J, Driessen B. Anesth Analg. 2005 Feb;100(2):437-9.

Does methemoglobin from oxidized hemoglobin-based oxygen carrier (hemoglobin Glutamer-200) interfere with lactate measurement (YSI 2700 SELECT Biochemistry Analyzer)?

2004

Gasthuys M, Alves S, Fenaille F, Tabet JC. Anal Chem. 2004 Nov 15;76(22):6628-34.

Simple identification of a cross-linked hemoglobin by tandem mass spectrometry in human serum.

2004

Cheung AT, Driessen B, Jahr JS, Duong PL, Ramanujam S, Chen PC, Gunther RA. Artif Cells Blood Substit Immobil Biotechnol. 2004 May;32(2):189-207.

Blood substitute resuscitation as a treatment modality for moderate hypovolemia.

2000

Jahr JS, Lurie F, Driessen B, Tang Z, Louie RF, Kullar R, Kost G. Clin Lab Sci. 2000 Summer;13(2):173-9.

Validation of oxygen saturation measurements in a canine model of hemoglobin based oxygen carrier (HBOC) infusion.

2003

Callan MB, Rentko VT. Vet Clin North Am Small Anim Pract. 2003 Nov;33(6):1277-93, vi. Review.

Clinical application of a hemoglobin-based oxygen-carrying solution.

2003

Strate T, Mann O, Kleinhans H, Schneider C, Knoefel WT, Yekebas E, Standl T, Bloechle C, Izbicki JR. Ann Surg. 2003 Nov;238(5):765-71.

Systemic intravenous infusion of bovine hemoglobin significantly reduces microcirculatory dysfunction in experimentally induced pancreatitis in the rat.

2003

Posner LP, Moon PF, Bliss SP, Gleed RD, Erb HN. Vet Anaesth Analg. 2003 Jan;30(1):30-6.

Colloid osmotic pressure after hemorrhage and replenishment with Oxyglobin Solution, hetastarch, or whole blood in pregnant sheep.

2003

Driessen B, Jahr JS, Lurie F, Golkaryeh MS, Gunther RA. Crit Care Med. 2003 Jun;31(6):1771-9.

Arterial oxygenation and oxygen delivery after hemoglobin-based oxygen carrier infusion in canine hypovolemic shock: a dose-response study.

2003

Lurie F, Driessen B, Jahr JS, Reynoso R, Gunther RA. Anesth Analg. 2003 Jan;96(1):46-50, table of contents.

Validity of arterial and mixed venous oxygen saturation measurements in a canine hemorrhage model after resuscitation with varying concentrations of hemoglobin-based oxygen carrier.

2002

Lurie F, Jahr JS, Driessen B. Am J Ther. 2002 Sep-Oct;9(5):425-30.

Changes in circulating blood and plasma volume after hemoglobin-based oxygen carrier infusion and additional infusion of colloid solutions.

2002

Hohenhaus AE. J Vet Intern Med. 2002 Jul-Aug;16(4):394-5.

Oxyglobin: a transfusion solution?

2001

Jahr JS, Driessen B, Lurie F, Tang Z, Louie RF, Kost G. Vet Clin Pathol. 2001;30(1):39-45.

Oxygen saturation measurements in canine blood containing hemoglobin glutamer-200 (Bovine): in vitro validation of the NOVA CO-Oximeter.

2002

Dorman SC, Kenny CF, Miller L, Hirsch RE, Harrington JP. Artif Cells Blood Substit Immobil Biotechnol. 2002 Jan;30(1):39-51.

Role of redox potential of hemoglobin-based oxygen carriers on methemoglobin reduction by plasma components.

2001

Muir W, Schertel ER. J Vet Pharmacol Ther. 2001 Dec;24(6):447-8.

Inadequacy of low-volume resuscitation with hemoglobin-based oxygen carrier hemoglobin glutamer-200 (bovine) in canine hypovolemia.

2001

Driessen B, Jahr JS, Lurie F, Gunther RA. Vet Anaesth Analg. 2001 Oct;28(4):204. doi: 10.1111/j.1467-2987.2001.00064.x. Epub 2016 Nov 15.

Low-volume resuscitation with a haemoglobin-based oxygen carrier Hemoglobin glutamer-200 (bovine) in canine hypovolaemia.

2001

Driessen B, Jahr JS, Lurie F, Griffey SM, Gunther RA. Vet Anaesth Analg. 2001 Oct;28(4):204-205. doi: 10.1111/j.1467-2987.2001.064-2.x. Epub 2016 Nov 15.

Effects of the haemoglobin-based oxygen carrier Hemoglobin glutamer-200 (bovine) on intestinal perfusion and oxygenation in a canine hypovolaemia model.

2001

McEwen MM, Moon-Massat PF, Butler EC, Kollias GV. Vet Anaesth Analg. 2001 Oct;28(4):214-219. doi: 10.1046/j.1467-2987.2001.00055.x. Epub 2016 Nov 15.

Polymerized bovine hemoglobin (Oxyglobin Solution) administration in two river otters (Lutra canadensis).

2001

Driessen B, Jahr JS, Lurie F, Griffey SM, Gunther RA. Br J Anaesth. 2001 May;86(5):683-92. Erratum in: Br J Anaesth 2001 Jul;87(1):164. Br J Anaesth 2001 Aug;87(2):329.

Effects of haemoglobin-based oxygen carrier hemoglobin glutamer-200 (bovine) on intestinal perfusion and oxygenation in a canine hypovolaemia model.

2001

Cheung AT, Jahr JS, Driessen B, Duong PL, Chan MS, Lurie F, Golkaryeh MS, Kullar RK, Gunther RA. Anesth Analg. 2001 Oct;93(4):832-8.

The effects of hemoglobin glutamer-200 (bovine) on the microcirculation in a canine hypovolemia model: a noninvasive computer-assisted intravital microscopy study.

2001

Driessen B, Jahr JS, Lurie F, Gunther RA. J Vet Pharmacol Ther. 2001 Feb;24(1):61-71.

Inadequacy of low-volume resuscitation with hemoglobin-based oxygen carrier hemoglobin glutamer-200 (bovine) in canine hypovolemia.

2001

Moon PF, Bliss SP, Posner LP, Erb HN, Nathanielsz PW. Vet Anaesth Analg. 2001 Apr;28(2):104-105. doi: 10.1046/j.1467-2987.2001.temp.doc.x-i10. Epub 2016 Nov 15.

Fetal oxygen content is restored with Oxyglobin resuscitation after maternal hemorrhage.

2001

Posner LP, Moon PF, Bliss SP, Gleed RD, Erb HN. Vet Anaesth Analg. 2001 Apr;28(2):104. doi: 10.1046/j.1467-2987.2001.temp.doc.x-i9. Epub 2016 Nov 15.

Plasma colloid osmotic pressure after blood volume repletion with Oxyglobin, hetastarch, or whole blood in pregnant sheep.

2001

Jahr JS, Lurie F, Xi S, Golkaryeh M, Kuznetsova O, Kullar R, Driessen B. Anesth Analg. 2001 Mar;92(3):609-14.

A novel approach to measuring circulating blood volume: the use of a hemoglobin-based oxygen carrier in a rabbit model.

1999

Braden TD, Tvedten HW, DeCamp CE, Turner TM, Hughes GS, Rentko VT. Am J Vet Res. 1999 Nov;60(11):1337-40.

Radiographic, biomechanical, and pathologic effects of hemoglobin glutamer-200 in dogs undergoing cemented total hip arthroplasty.

674 Souder Road
Souderton, PA 18964
+1 (267) 382 0064
info@hbo2therapeutics.com

Download latest news

Download latest news

Stay up to date